文献速递乳房整形与再造美容整形

重新审视缩乳术:肿瘤整形与症状性巨乳缩乳术的并发症

Revisiting Reduction Mammaplasty: Complications of Oncoplastic and Symptomatic Macromastia Reductions.
PubMed 文献 · Plast Reconstr Surg · 2022-11-08

回顾性分析单机构两年内632个乳房缩乳术(502例缩乳术、85例对称性缩乳、45例肿瘤整形缩乳),各类手术在乳头坏死、伤口愈合等并发症率上相似,但术后修整率在缩乳术2%、肿瘤整形缩乳6.7%、对称性缩乳5.9%间存在显著差异(P=0.027)。糖尿病、吸烟和高BMI是多因素分析中保留的显著危险因素。

要点

  • 肿瘤整形缩乳与症状性巨乳缩乳的并发症谱相似且可接受地低。
  • 术后修整率:缩乳术2% vs 肿瘤整形缩乳6.7% vs 对称性缩乳5.9%,差异显著(P=0.027)。
  • 多因素分析中糖尿病(P=0.047)、吸烟(P=0.025)和高BMI(P=0.002)为显著危险因素。

核心结论

  • 肿瘤整形乳房缩乳术与症状性巨乳缩乳术的并发症谱相似且可接受地低。

研究设计与样本

  • 回顾性综述,纳入单机构两位整形外科医生连续2年施行的所有缩乳术病例,共分析342例患者的632个乳房。

主要发现

  • 共分析632个乳房:缩乳术502个、对称性缩乳85个、肿瘤整形缩乳45个,来自342例患者。
  • 平均年龄43.9±15.93岁,平均体重指数29.15±5.66 kg/m2,平均缩乳重量610.03±313.13 g。
  • 86%的病例采用内侧蒂技术。
  • 乳头坏死、伤口愈合、瘢痕修整、脂肪坏死、血清肿、血肿及总体并发症率在所有手术间相似。
  • 术后修整率在缩乳术(2%)、肿瘤整形缩乳(6.7%)和对称性缩乳(5.9%)间存在显著差异(P=0.027)。

关键数值与推荐

  • 多因素逻辑回归模型中,糖尿病(P=0.047)、吸烟(P=0.025)和较高体重指数(P=0.002)均保留为统计学显著危险因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oncoplastic breast reduction has been shown to be an effective and safe approach to breast conservation surgery in women with macromastia. However, there remains a paucity of data investigating the comparative outcomes. This study seeks to delineate the complication profiles for oncoplastic and symmetrizing breast reductions versus mammaplasty for benign macromastia. METHODS: A retrospective review was conducted of all consecutively performed reduction mammaplasty cases at a single institution by two plastic surgeons over a 2-year period. RESULTS: A total of 632 breasts were analyzed: 502 reduction mammaplasties, 85 symmetrizing reductions, and 45 oncoplastic reductions in 342 patients. Mean age was 43.9 ± 15.93 years, mean body mass index was 29.15 ± 5.66 kg/m2, and mean reduction weight was 610.03 ± 313.13 g. Regarding surgical technique, a medial pedicle was used in 86% of cases. There were similar postoperative complication outcomes for nipple necrosis, wound healing, scar revision, fat necrosis, seroma, hematoma, and overall complication rates for all procedures. However, the rate of postoperative revision among reduction mammaplasty (2%), oncoplastic reduction (6.7%), and symmetrizing reduction (5.9%) was significantly different (P = 0.027). In univariate analysis, diabetes (P = 0.011), smoking (P = 0.007), higher body mass index (P = 0.003), larger reduction weight (P = 0.011), longer nipple-to-inframammary fold measurement (P = 0.014), and longer sternal notch-to-nipple measurement (P = 0.039) were all significant risk factors for a surgical complication in reductions performed for any indication. Using a multivariate logistic regression model, diabetes (P = 0.047), smoking (P = 0.025), and higher body mass index (P = 0.002) were all retained as statistically significant risk factors. CONCLUSION: The complication profiles for both oncoplastic breast reductions and breast reductions for symptomatic macromastia are similar and acceptably low. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Morrison KA, Frey JD, Karp N, et al. Revisiting Reduction Mammaplasty: Complications of Oncoplastic and Symptomatic Macromastia Reductions. Plast Reconstr Surg. 2022. PMID: 36696305. doi:10.1097/PRS.0000000000009828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。